PharmaCyte Biotech, Inc.
PMCB
$0.9411
$0.00730.78%
NASDAQ
| 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 9,083.97% | 1,877.84% | 1,866.55% | 552.43% | 107.73% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -1,156.80% | -2,145.37% | -4,593.89% | -898.83% | -439.77% |
| Change in Net Operating Assets | 353.95% | 323.97% | 84.85% | -75.26% | 200.54% |
| Cash from Operations | -38.43% | -7.78% | 21.58% | -21.19% | 43.29% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -40.00% | -40.00% | -- | -- | -- |
| Cash from Investing | -40.00% | -40.00% | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -100.00% | -100.00% | -100.00% | -88.89% |
| Repurchase of Common Stock | 90.98% | 88.68% | 89.28% | 93.45% | -107.94% |
| Issuance of Preferred Stock | -- | -100.00% | -100.00% | -100.00% | -- |
| Repurchase of Preferred Stock | -28.42% | -300.71% | -2,487.37% | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 200.00% | -- |
| Cash from Financing | -133.74% | -723.48% | -3,557.09% | -423.24% | 21.03% |
| Foreign Exchange rate Adjustments | 25.00% | 75.47% | 111.11% | 91.36% | 94.52% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -96.01% | -292.19% | -1,386.55% | -455.54% | -2.88% |